Antenatal Betamethasone for Women at Risk for Late Preterm Delivery
Source: View publication →
The ALPS trial demonstrated that a single course of antenatal betamethasone in women at high risk of late preterm delivery (34 0/7 to 36 6/7 weeks) significantly reduces short-term neonatal respiratory morbidity compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ALPS trial shifted obstetric clinical practice by providing evidence to support the administration of antenatal corticosteroids for late preterm pregnancies (34 0/7 to 36 6/7 weeks) at risk of imminent delivery, which is now a standard of care endorsed by ACOG to mitigate neonatal respiratory morbidity.
Historical Context
Prior to the ALPS trial, the use of antenatal corticosteroids was well-established for pregnancies at risk of preterm delivery before 34 weeks gestation. However, there was a major evidence gap for the 'late preterm' period, as neonatal survival in this period is high and the benefit-to-risk ratio of steroid exposure had not been rigorously tested in a large, randomized controlled trial until this study.
Guided Discussion
High-yield insights from every perspective
What is the biochemical mechanism by which antenatal betamethasone promotes fetal lung maturity, and why is this intervention traditionally associated with gestation before 34 weeks?
Key Response
Betamethasone induces the maturation of Type II pneumocytes, increasing the production and release of surfactant which reduces alveolar surface tension. Traditionally, the focus was on deliveries before 34 weeks because surfactant production naturally increases significantly after this point, leading to the assumption that late preterm infants (34 0/7 to 36 6/7 weeks) would not benefit from exogenous corticosteroids.
A patient at 35 weeks gestation presents with preterm labor and 4cm cervical dilation. According to the ALPS trial, what is the primary neonatal benefit of administering betamethasone, and what specific neonatal metabolic complication occurred more frequently in the treatment group?
Key Response
The ALPS trial found a significant reduction in the primary composite outcome of neonatal respiratory support (CPAP or oxygen for >= 6 hours, surfactant, mechanical ventilation, etc.). However, neonatal hypoglycemia was significantly more common in the betamethasone group compared to placebo (24.0% vs. 15.0%), necessitating close glucose monitoring in these neonates.
The ALPS trial demonstrated a reduction in 'respiratory morbidity,' yet the majority of the benefit was driven by a reduction in Transient Tachypnea of the Newborn (TTN) and CPAP use rather than RDS or mechanical ventilation. How does this shift the risk-benefit analysis for late preterm steroids compared to early preterm steroids?
Key Response
In early preterm delivery (<34 weeks), steroids reduce high-mortality conditions like RDS, IVH, and NEC. In the late preterm period, the morbidity being prevented (like TTN) is typically transient and less severe. Therefore, the 'benefit' side of the scale is lighter, making potential long-term risks or short-term issues like hypoglycemia more influential in the clinical decision-making process.
In the ALPS trial, approximately 15% of women in the treatment group did not deliver before 37 weeks. How should the risk of 'unnecessary' steroid exposure in the late preterm period influence our clinical threshold for administration, especially given concerns regarding long-term neurodevelopmental or metabolic programming?
Key Response
The ALPS trial showed that many women identified as being 'at risk' for late preterm delivery will actually carry to term. Because the neonatal benefits are for relatively mild respiratory morbidity, clinicians should strictly adhere to the study's inclusion criteria (e.g., cervical dilation >= 3cm or ruptured membranes) to avoid over-treating the significant number of women whose 'threatened' labor does not result in imminent delivery.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ALPS trial utilized a composite primary outcome. Analyze the methodological implications of including 'respiratory support for at least 6 hours' alongside 'surfactant use' or 'mechanical ventilation' in a population with low baseline event rates.
Key Response
Using a composite outcome increases statistical power in populations where severe events (like mechanical ventilation) are rare. However, if the treatment effect is primarily driven by the most frequent and least severe component (CPAP/oxygen for 6 hours), the 'significant' result may overstate the clinical impact on infant health. Methodologically, this requires a sensitivity analysis of the individual components to ensure the composite isn't masking a lack of effect on more clinically 'hard' endpoints.
If you were reviewing the ALPS trial for publication, how would you evaluate the high rate of neonatal hypoglycemia in the treatment group regarding its impact on the study's 'Net Clinical Benefit'?
Key Response
A tough reviewer would flag that while respiratory morbidity decreased, a significant iatrogenic morbidity (hypoglycemia) was introduced. The editor would look for whether the study was powered to detect the consequences of that hypoglycemia (e.g., longer NICU stays or neurodevelopmental impact) and whether the 'reduction in respiratory support' outweighs the 'increase in metabolic monitoring and potential interventions' for hypoglycemia.
ACOG and SMFM guidelines now recommend a single course of betamethasone for women at risk of delivery between 34 0/7 and 36 6/7 weeks, but with specific caveats. How do these guidelines address patients with pre-gestational diabetes, and how does this align with the ALPS study population?
Key Response
Current guidelines (ACOG Practice Bulletin 209) recommend avoiding late preterm steroids in women with pre-gestational diabetes because the ALPS trial specifically excluded women with pre-gestational diabetes. This is due to the significant risk of maternal hyperglycemia and the already elevated baseline risk of neonatal hypoglycemia in diabetic pregnancies, which betamethasone would likely exacerbate.
Clinical Landscape
Noteworthy Related Trials
Collaborative Group on Antenatal Steroid Therapy
Tested
Antenatal dexamethasone
Population
Women at risk of preterm delivery between 28-34 weeks gestation
Comparator
Placebo
Endpoint
Neonatal respiratory distress syndrome and mortality
ACTORDS Trial
Tested
Repeat dose of antenatal corticosteroids
Population
Women at risk of preterm birth who received an initial course more than 7 days prior
Comparator
Placebo
Endpoint
Composite of serious neonatal morbidity
Follow-up Study of the ALPS Trial
Tested
Antenatal betamethasone
Population
Children exposed to betamethasone in late preterm period
Comparator
Placebo
Endpoint
Social-emotional and neurodevelopmental outcomes at 2 years of age
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis